Ascensia is the exclusive global distribution partner for Eversense® - the first and only long-term Continuous Glucose Monitoring System. The company combines established diabetes-management technology with expansion into continuous glucose monitoring, positioning itself as a comprehensive diabetes care provider. Ascensia has formed alliances and partnerships with other companies and organizations to advance diabetes care, including partnerships with Medtronic, Voluntis, and Insulet.
Cyborg Score Rationale
Ascensia operates in a high-growth diabetes care market with established flagship products (CONTOUR) and strategic distribution of innovative CGM technology (Eversense). The company demonstrates solid market presence in 90+ countries and revenue of ~$750M (April 2025), supported by key partnerships. However, as a private subsidiary, it faces competitive pressures from larger public medical device players.
Top Insights
As of April 2025, Ascensia Diabetes Care's annual revenue reached $750M
As of April 2025, Ascensia Diabetes Care has approximately 1.4K employees across 6 continents, including Europe, North America, and Asia
Eversense has been granted an integrated CGM (iCGM) designation by the US Food and Drug Administration (FDA), as the first fully implantable device in this category
Ascensia has more than 80 years of history helping people manage their diabetes, benefiting from legacy technology and brand recognition in blood glucose monitoring
Named Competitors
FreeStyle Libre — Flash glucose monitoring system for diabetes management
Dexcom G6/G7 — Continuous glucose monitoring with real-time glucose data
OneTouch — Blood glucose monitoring systems and diabetes management solutions
Guardian — Continuous glucose monitoring for insulin pump integration
Recent Developments
(March 2024) Eversense received FDA iCGM designation as first fully implantable CGM with integrated capabilities
(October 2023) Ascensia Diabetes Care Poland awarded Great Place To Work certification
(April 2025) Annual revenue reported at $750M; approximately 1.4K employees
Open the full interactive Ascensia Diabetes Care report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.